ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.
Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:
• Person of any age
• Have a reference pathology report suggesting Castleman disease not limited to cutaneous involvement only that can be uploaded
• Be able to provide electronic informed consent, as per local regulations
• Deceased patients may also be enrolled when a reference pathology report suggesting Castleman disease can be supplied or when the ART is able to locate and upload such a pathology report.
Locations
United States
Pennsylvania
University of Pennsylvania
RECRUITING
Philadelphia
Contact Information
Primary
Joshua Brandstadter, MD, PhD, MSc
joshua.brandstadter@pennmedicine.upenn.edu
267-847-8220
Backup
Bridget Austin, MSc
accelerate@uphs.upenn.edu
2675869977
Time Frame
Start Date: 2016-10
Estimated Completion Date: 2027-09
Participants
Target number of participants: 1000
Authors
David C Fajgenbaum, Eric Oksenhendler, Christian Hoffmann, Linus Angenendt, Louis Terriou, Andrea Nozza, James Cavet, Matthew Streetly, Simone Ferrero, Pier L Zinzani
Related Therapeutic Areas
Sponsors
Leads: University of Pennsylvania
Collaborators: EUSA Pharma, Inc., Castleman Disease Collaborative Network